Veracyte(US:VCYT) ZACKS·2025-11-11 13:31Core Insights - Veracyte, Inc. (VCYT) reported a significant increase in adjusted earnings for Q3 2025, reaching 51 cents per share, a 54.5% improvement from the previous year, and exceeding the Zacks Consensus Estimate by 59.4% [1][7] - The company's revenues grew by 13.8% year over year to $131.9 million, surpassing the Zacks Consensus Estimate by 5.5% [2][7] - Following the earnings announcement, VCYT's share price increased by 27.5% [2] Revenue Performance - Testing revenues accounted for $127.8 million, reflecting a 17% year-over-year increase, driven by Decipher and Afirma revenue growth of 26% and 7%, respectively [3] - Product revenues rose by 4% year over year to $3.3 million, while biopharmaceutical and other revenues decreased by 74.2% to $0.8 million [3] Cost and Margins - Total cost of revenues increased by 11.6% year over year to $37.9 million, while gross profit rose by 14.7% to $94 million, leading to a gross margin expansion of 56 basis points to 71.3% [4] - Adjusted operating margin improved by 612 basis points year over year to 19.9% [4] Cash and Capital Structure - At the end of Q3 2025, Veracyte had cash and cash equivalents of $315.6 million, up from $219.5 million at the end of Q2 [5] - Cumulative net cash from operating activities increased to $83.7 million compared to $50.6 million a year ago [5] Guidance Updates - Veracyte raised its full-year 2025 testing revenue guidance to a range of $484-$487 million, indicating a year-over-year growth of 17% to 18% [6] - The total revenue guidance for 2025 was also raised to $506-$510 million, implying a 14% year-over-year growth [8] - Adjusted EBITDA as a percentage of revenues is now expected to exceed 25%, up from the previous guidance of 23.5% [9] Notable Developments - The company launched Afirma v2 transcriptome to enhance the efficiency of its testing business and completed enrollment for the NIGHTINGALE clinical utility trial for the Percepta Nasal Swab test [11]